title: [Role of bone-density-conserving agents in the treatment for pain in patients with bone metastases].
abstract: Bones are the fourth area of metastases of malignant tumors that significantly burden the disease reducing the quality of life of a patient as cause pain, threat pathological fracture, deteriorate limb function, and develop hypercalcemia. Treatment of patients should be comprehensive and base on the rational use of systemic therapy and local impacts. The use of bisphosphonates inhibits bone resorption and progression of bone metastases, reduces the risk of complications due to metastatic bone disease including pain. Bisphosphonates significantly reduce the incidence of SRE in patients with bone metastases, diminish the need for analgesic radiotherapy, postpone terms of SRE occurrence, reduce pain syndrome as well as the need for analgetics. They also easily tolerated by patients.
authors.forename: A S
authors.initials: AS
authors.lastname: Zhabina
authors.forename: T Yu
authors.initials: TY
authors.lastname: Semiglazova
mesh_terms: D000700:Analgesics / Q000008:administration & dosage; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000150:complications* / Q000556:secondary; D001862:Bone Resorption / Q000517:prevention & control; D004164:Diphosphonates / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D010146:Pain / Q000188:drug therapy / Q000209:etiology*; D059408:Pain Management / Q000379:methods*; D011788:Quality of Life
chemical_list: D000700:Analgesics; D050071:Bone Density Conservation Agents; D004164:Diphosphonates